Skip to main content

Table 3 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 3

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

 Genotype 3 SVR, % (95% CI)Genotype 3a SVR, % (95% CI)Genotype 3b SVR, % (95% CI)
All patientsAll patientsLDV/SOFDAC + SOFSOF/VELAll patientsLDV/SOFDAC + SOFSOF/VEL
Patients who complete, N30321671862328NA271
 All durations96.7 (94.0–98.2)97.2 (94.1–98.7)85.7 (48.7–97.4)98.4 (95.4–99.5)91.3 (73.2–97.6)89.3 (72.8–96.3)NA88.9 (71.9–96.1)100 (20.7–100)
 12-wk treatment96.3 (92.8–98.1)96.9 (92.9–98.6)80.0 (37.6–96.4)98.5 (94.6–99.6)91.3 (73.2–97.6)88.9 (67.2–96.9)NA88.2 (65.7–96.7)100 (20.7–100)
 16-wk treatment93.5 (79.3–98.2)93.8 (71.7–98.9)NA93.8 (71.7–98.9)NA83.3 (43.6–97.0)NA83.3 (43.6–97.0)NA
 24-wk treatment100 (93.8–100)100 (91.4–100)100 (34.2–100)100 (91.0–100)NA100 (51.0–100)NA100 (51.9–100)NA
SVR in the following subgroups
 No cirrhosis99.0 (94.8–99.8)100 (95.1–100)100 (34.2–100)100 (94.6–100)100 (61.0–100)90.9 (62.3–98.4)NA90.9 (62.3–98.4)NA
 Cirrhosis95.5 (91.6–97.6)95.7 (91.0–98.0)80.0 (37.6–96.4)97.5 (92.8–99.1)88.2 (65.7–96.7)88.2 (65.7–96.7)NA87.5 (64.0–96.5)100 (20.7–100)
 Decompensated cirrhosis88.4 (75.5–94.9)86.7 (70.3–94.7)100 (20.7–100)91.7 (74.2–97.7)80.0 (37.6–96.4)100 (61.0–100)NA100 (61.0–100)NA
 Treatment-naive96.8 (92.7–98.6)95.5 (89.8–98.0)66.7 (20.8–93.9)96.6 (90.6–98.8)94.4 (74.2–99.0)100 (84.5–100)NA100 (84.5–100)NA
 Treatment-experienced96.6 (92.3–98.5)99.1 (94.8–99.8)100 (51.0–100)100 (96.2–100)80.0 (37.6–96.4)57.1 (25.0–84.2)NA50.0 (18.8–81.2)100 (20.7–100)